| Background and Objective:Lung cancer has become the most common cancer in China,and it is also has the highest mortality rate.Commonly used treatments for lung cancer include surgery,radiotherapy,chemotherapy,target therapy,and immunotherapy.Currently there are no standard treatment options for patients with advanced non-small cell lung cancer who have failed previous second-line treatment.Continued three-line chemotherapy is inefficient,and the adverse reactions are severe,and the prolongation of survival is not significant.Patients with negative genetic testing can hardly benefit from target therapy,and patients with positive mutations also have resistance problems after receiving 3~rdd genenration target therapy for a certain period of time.Therefore,we need new lung cancer target therapies to address the predicament of advanced non-small cell lung cancer treatment.Methods:Anlotinib12 mg qd for 2 weeks and rest for 1 week for a total of 3 weeks for1 cycle until progression or intolerable adverse events occurred.The efficacy was evaluated by the RECIST 1.1 standard,the adverse events were evaluated by CTCAE4.02,and the quality of life was measured by the EORTC QLQ-C30 and the lung cancer special scale QLQ-LC13.The t-test was used to compare the scales before and after the treatment.The difference was statistically significant at p<0.05.Results:Among 27 patients in study,no complete response(CR)was found,2 patients(7.4%)achieved partial response(PR),16 patients(59.3%)achieved stable disease(SD),9 patients(33.3%)achieved progressive disease(PD),objective response rate(ORR)was 7.4%,and disease control rate(DCR)was 66.7%.The scores of physical functioning(76.00±10.55 vs.64.44±11.59),emotional functioning(81.67±8.71 vs.76.11±6.71)and global health status(48.87±7.97 vs.40.56±12.49)of the QLQ-C30scale after treatment were higher than those before treatment,with statistically significant differences(t=﹣4.516,P<0.001;t=﹣2.646,P=0.019;t=﹣3.872,P=0.002).Fatigue(50.37±8.95 vs.40.74±13.86),nausea and vomiting(26.54±16.18 vs.14.20±11.97),loss of appetite[33.33(33.33)vs.33.33(33.33)]were better than before(t=﹣2.476,P=0.027;t=﹣5.036,P<0.001;Z=﹣2.923,P=0.003);pain(28.88±14.23 vs.33.33±13.60)and dyspnea[33.33(33.33)vs.33.33(66.67)]scores were lower than before(t=3.674,P=0.003;Z=﹣3.266,P=0.001).The scores of cough(24.44±19.12 vs.45.24±20.34),shortness of breath[11.11(22.22)vs.33.33(22.22)]and chest pain[M(QR):0.00(33.33)vs.33.33(33.33)]in the QLQ-LC13 scale after treatment were lower than those before treatment,with statistically significant differences(t=4.000,P=0.001;t=4.836,P<0.001;Z=﹣1.890,P=0.034);the scores of sore mouth or tongue[0.00(33.33)vs.0.00(0.00)]and hands and feet tingling[33.33(33.33)vs.0.00(0.00)]were higher than before(Z=﹣2.000,P=0.046;Z=﹣2.264,P=0.024).Common adverse reactions included hypertension,fatigue,elevated thyroid stimulating hormone,proteinuria,hand-foot syndrome,oral mucositis,hemoptysis,etc,mainly grade 1-2,and they were all improved after the treatments.Conclusion:The treatment of advanced non-small cell lung cancer with Anlotinib has a certain degree of clinical efficacy,can relieve clinical symptoms to a certain extent,adverse reactions can be tolerated and improve the quality of life. |
PDF Full Text Request